ERCC1 and non-small cell lung carcinoma: Here, we report the outcomes of NSCLC patients according to the ERCC-1 SNPs status and attempt to evaluate the role of these genetic alterations as possible future, hypothetical, promising biomarkers of response/clinical benefit to nivolumab.